These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37216363)

  • 1. Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias.
    Vrablík M; Šarkanová I; Breciková K; Šedová P; Šatný M; Tichopád A
    PLoS One; 2023; 18(5):e0272883. PubMed ID: 37216363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.
    Haberka M; Okopień B; Gąsior Z
    Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
    Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
    Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands.
    Heintjes EM; Anastassopoulou A; Kuiper J; Bilitou A; Beest FJAP; Herings RMC; Postma MJ; Jukema JW
    Curr Med Res Opin; 2023 Jan; 39(1):1-11. PubMed ID: 36168818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
    Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
    Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　- A Retrospective Database Analysis.
    Umeda T; Hayashi A; Harada A; Okuyama K; Baxter CA; Tokita S; Teramoto T
    Circ J; 2018 May; 82(6):1605-1613. PubMed ID: 29628458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
    Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
    Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.